カテゴリ： GlobalData, アメリカ, 企業調査

Tesaro Inc (TSRO)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Tesaro Inc (TSRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014186
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is approved for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. The company distributes the product in the US principally through specialty distributors and specialty pharmacy channel. Its development portfolio includes novel cancer and supportive care product candidates in various development stages. Tesaro is headquartered in Waltham, Massachusetts, the US.

Tesaro Inc (TSRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tesaro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Tesaro Inc, Medical Devices Deals, 2011 to YTD 2017 10
Tesaro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Tesaro Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
TESARO Secures US$101 Million In Series B Venture Financing 13
Partnerships 15
Evotec and Tesaro Enter into Agreement 15
OncoQuest Enters into Agreement with Tesaro 16
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 17
Licensing Agreements 18
Millennium Pharma Enters into Licensing Agreement with Tesaro 18
Zai Lab Enters into Licensing Agreement with Tesaro 19
Janssen Biotech Enters into Licensing agreement with Tesaro 20
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 21
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 22
Tesaro Amends Licensing Agreement With AnaptysBio 23
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 24
Tesaro Enters Into Licensing Agreement With Amgen 25
Equity Offering 26
Tesaro Raises USD236.3 Million in Public Offering of Shares 26
Tesaro Raises USD433.2 Million in Public Offering of Shares 28
Tesaro Raises USD50 Million in Private Placement of Shares 30
Tesaro Raises up to USD155 Million in Private Placement of Shares 31
Tesaro Raises USD191.5 Million in Public Offering of Shares 33
Tesaro Completes Public Offering Of Shares For US$100.8 Million 35
Tesaro Completes Public Offering Of Common Stock For US$98 Million 36
Tesaro Announces Partial Exercise Of Underwriter’s Option For IPO For US$87 Million 37
Debt Offering 39
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 39
Acquisition 41
Tesaro May Sell Itself 41
Tesaro Inc – Key Competitors 42
Tesaro Inc – Key Employees 43
Tesaro Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 45
Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 47
May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 49
Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 51
Nov 03, 2016: TESARO Announces Third-Quarter 2016 Operating Results 53
Aug 04, 2016: Tesaro Announces Second-Quarter 2016 Operating Results 55
May 05, 2016: TESARO Announces First-Quarter 2016 Operating Results 57
Feb 25, 2016: TESARO Announces Fourth-Quarter 2015 Operating Results 59
Corporate Communications 61
Apr 04, 2016: TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors 61
Product News 62
09/06/2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting 62
06/23/2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer 63
05/18/2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting 64
02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 65
01/11/2016: Tesaro Outlines Business Priorities And Strategic Outlook For 2016 66
Product Approvals 68
Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 68
Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing 69
Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA 70
Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency 71
Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration 72
Clinical Trials 73
Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment 73
Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing 74
Mar 29, 2016: TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042 75
Other Significant Developments 76
Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 76
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Tesaro Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tesaro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tesaro Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Tesaro Inc, Medical Devices Deals, 2011 to YTD 2017 10
Tesaro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
TESARO Secures US$101 Million In Series B Venture Financing 13
Evotec and Tesaro Enter into Agreement 15
OncoQuest Enters into Agreement with Tesaro 16
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 17
Millennium Pharma Enters into Licensing Agreement with Tesaro 18
Zai Lab Enters into Licensing Agreement with Tesaro 19
Janssen Biotech Enters into Licensing agreement with Tesaro 20
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 21
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 22
Tesaro Amends Licensing Agreement With AnaptysBio 23
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 24
Tesaro Enters Into Licensing Agreement With Amgen 25
Tesaro Raises USD236.3 Million in Public Offering of Shares 26
Tesaro Raises USD433.2 Million in Public Offering of Shares 28
Tesaro Raises USD50 Million in Private Placement of Shares 30
Tesaro Raises up to USD155 Million in Private Placement of Shares 31
Tesaro Raises USD191.5 Million in Public Offering of Shares 33
Tesaro Completes Public Offering Of Shares For US$100.8 Million 35
Tesaro Completes Public Offering Of Common Stock For US$98 Million 36
Tesaro Announces Partial Exercise Of Underwriter’s Option For IPO For US$87 Million 37
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 39
Tesaro May Sell Itself 41
Tesaro Inc, Key Competitors 42
Tesaro Inc, Key Employees 43
Tesaro Inc, Subsidiaries 44

★海外企業調査レポート[Tesaro Inc (TSRO)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • KDDI Corporation (9433)：企業の財務・戦略的SWOT分析
    KDDI Corporation (9433) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Gulfport Energy Corp (GPOR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Gulfport Energy Corp (Gulfport) is an oil and gas company that explores, develops and produces oil and natural gas. The company operates its oil and gas exploration and development assets in Utica Shale, West Cote Blanche Bay Field, Hackberry Field, Athabasca, Peace River oil and Cold Lake o …
  • Barkers (Northallerton) Limited：企業の戦略的SWOT分析
    Barkers (Northallerton) Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • InCarda Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary InCarda Therapeutics Inc (InCarda) is a biopharmaceutical company that concentrates on the development of transformative therapies for cardiovascular conditions through the inhalation route. The company’s lead product candidate includes InRhythm, an inhaled antiarrhythmic for acute treatment …
  • Nuvo Pharmaceuticals Inc (NRI)-製薬・医療分野：企業M&A・提携分析
    Summary Nuvo Pharmaceuticals Inc (Nuvo), formerly known as Nuvo Research Inc is a drug company that offers topical pain products and technologies. The company’s product portfolio includes pennsaid, pennsaid 2%, and heated lidocaine and tetracaine patches. Its products deliver drugs topically into an …
  • PledPharma AB (PLED)：企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. PledOX drug is used to prevent chemotherapy-induced side effects for colorectal …
  • Synchrony Financial：企業の戦略・SWOT・財務情報
    Synchrony Financial - Strategy, SWOT and Corporate Finance Report Summary Synchrony Financial - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • National Grid Plc：企業の発電所・SWOT分析2018
    National Grid Plc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Terumo BCT Inc：企業の戦略的SWOT分析
    Terumo BCT Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Abcam Plc (ABC)：医療機器：M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • Leukemia & Lymphoma Society Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a voluntary health organization that focuses on funding research for identifying cure for blood cancer. The organization also assures access to treatments for blood cancer patients. Its offers patient support, health education, policy advocacy, an …
  • Shimadzu Corp (7701)：医療機器：M&Aディール及び事業提携情報
    Summary Shimadzu Corp (Shimadzu) is a manufacturer of precision instruments, measuring instruments and medical equipment. The company’s product portfolio includes high performance liquid chromatographs (HPLC), spectrometers, carbon analyzer, X-ray systems, inspection systems, semiconductor manufactu …
  • Acorn Energy Inc (ACFN)：石油・ガス：M&Aディール及び事業提携情報
    Summary Acorn Energy Inc (Acorn) is an energy technology holding company which operates electricity delivery, emergency back-up power generation, and remote monitoring and control systems through its subsidiaries. The company develops and produces sonar systems for the defense, HLS, energy and comme …
  • Singulex Inc-製薬・医療分野：企業M&A・提携分析
    Summary Singulex Inc (Singulex) is a medical device company develops single molecule counting technology. The company provides Sgx clarity system, an in vitro diagnostics platform that provides high sensitivity next generation immunodiagnostics. Its proprietary SMC technology allows scientists and p …
  • Lycatel Services Limited：企業の戦略的SWOT分析
    Lycatel Services Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Aker BioMarine AS：企業の戦略・SWOT・財務分析
    Aker BioMarine AS - Strategy, SWOT and Corporate Finance Report Summary Aker BioMarine AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Gilead Sciences, Inc.：戦略・SWOT・企業財務分析
    Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ebiquity plc (EBQ)：企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company’s services include marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data analy …
  • Edison International (EIX)：企業の財務・戦略的SWOT分析
    Edison International (EIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nutra Pharma Corp (NPHC)：企業の財務・戦略的SWOT分析
    Nutra Pharma Corp (NPHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆